Loar Holdings Inc. filed its Form 10-Q with the Securities and Exchange Commission on November 5, 2026, covering the quarterly period ended September 30, 2026, reporting net sales of $176.2 million and net income of $19.6 million for the third quarter.
NeOnc Technologies Holdings, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the period ended September 30, 2026, and reporting a significant increase in cash and a continued stockholders' deficit.
White Mountains Insurance Group, Ltd. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026, reporting consolidated total assets of $13,362.6 million as of that date.
National Fuel Gas Company filed a Form 8-K with the SEC on November 5, 2026, reporting the issuance of a press release on November 4, 2026, covering earnings for the quarter and fiscal year ended September 30, 2026.
CRA International, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter and year-to-date period ended October 3, 2026.
Hertz Global Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing condensed consolidated financial statements for the three and nine months ended September 30, 2026.
Donegal Mutual Insurance Co filed a Form 4 with the SEC on November 5, 2026, disclosing two open-market purchases of Donegal Group Inc Class A Common Stock on November 3 and November 4, 2026.
Camden National Corporation filed an 8-K on November 5, 2026, disclosing under Regulation FD that it had prepared an investor presentation for upcoming investor meetings, furnished as Exhibit 99.1.
CRA International, Inc. filed an 8-K on November 5, 2026, reporting financial results for its fiscal quarter ended October 3, 2026, and announcing a quarterly cash dividend of $0.67 per share on its common stock.
Processa Pharmaceuticals, Inc. filed Definitive Additional Materials (DEFA14A) on November 5, 2026, disclosing a stockholder letter explaining the July 2026 Vidya Therapeutics acquisition, the resulting capitalization structure, and the company's development plans for lead candidate VT-7208.